InterCure To Buy ISHI In All-Stock Transaction – Find Out More

InterCure (INCR) on Friday announced that it will acquire premium medical cannabis technology and brand company Botanico, also known as ISHI.  

The company said that it would acquire ISHI in two phases. The company would initially acquire 50% of equity for about 2.47 million InterCure ordinary shares. The remaining 50% will be acquired either 24 months from the initial closing, in consideration for an additional 2.46 million InterCure ordinary shares, or upon ISHI achieving positive operating profitability for at least three consecutive months, InterCure said.

INCR stock traded 2% higher at the time of writing. On Stocktwits, retail sentiment around INCR stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.

InterCure said that the acquisition comes as the Trump administration reportedly explores the rescheduling of cannabis from Schedule I to Schedule III. This regulatory shift could unlock unprecedented opportunities for international cannabis companies such as InterCure, it added.

InterCure stated that the acquisition would provide access to ISHI's premium indoor product supply, brand portfolio, technology, and operational systems, which will enhance the former’s supply chain and distribution operations while supporting expansion into international markets. The company will also gain access to exclusive partnerships with premium U.S. brands, such as medical cannabis company The Flowery.

Following the acquisition, ISHI founders Omer Layani and Dor Hershkovitz will join the InterCure leadership team, and all existing ISHI stock options will be converted to InterCure options, maintaining the original vesting schedules.

"By acquiring ISHI, we gain immediate access to some of America's most sought-after cannabis genetics and proven operational technologies at exactly the moment when we are encouraged by the reported recent momentum in the U.S. around potential cannabis rescheduling,” said CEO Alexander Rabinovich, while adding that the company expects it to become accretive to its business model within the first year.

The transaction is expected to close in the first quarter of 2026, subject to regulatory approvals.

INCR stock has fallen 4% this year and by approximately 18% over the past 12 months. 

Read also: Intellia Therapeutics Stock Gets A Price Target Hike From HC Wainwright – Check Out The Details

For updates and corrections, email newsroom[at]stocktwits[dot]com.